Eton Pharmaceuticals Inc (ETON) - Total Assets
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) holds total assets worth $115.81 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eton Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see ETON company net worth for the company's overall valuation and market capitalisation.
Eton Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Eton Pharmaceuticals Inc's total assets of $115.81 Million consist of 65.8% current assets and 34.2% non-current assets. Review Eton Pharmaceuticals Inc (ETON) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.2% |
| Accounts Receivable | $11.76 Million | 12.8% |
| Inventory | $15.42 Million | 16.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $30.88 Million | 33.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ETON live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eton Pharmaceuticals Inc's current assets represent 65.8% of total assets in 2025, a decrease from 98.9% in 2017.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, down from 97.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 33.5% of total assets.
Eton Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eton Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs179.65 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Eton Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.77 | 4.83 |
| Quick Ratio | 1.30 | 1.16 | 4.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $23.48 Million | $29.85 Million | $20.50 Million |
Eton Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eton Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 36.46 |
| Latest Market Cap to Assets Ratio | 17.22 |
| Asset Growth Rate (YoY) | 21.0% |
| Total Assets | $92.11 Million |
| Market Capitalization | $1.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Eton Pharmaceuticals Inc's assets at a significant premium (17.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eton Pharmaceuticals Inc's assets grew by 21.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of Eton Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $92.11 Million | +21.01% |
| 2024-12-31 | $76.12 Million | +139.83% |
| 2023-12-31 | $31.74 Million | +26.81% |
| 2022-12-31 | $25.03 Million | -8.87% |
| 2021-12-31 | $27.46 Million | +4.35% |
| 2020-12-31 | $26.32 Million | +54.16% |
| 2019-12-31 | $17.07 Million | -39.73% |
| 2018-12-31 | $28.33 Million | +110.72% |
| 2017-12-31 | $13.44 Million | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more